Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Nutr ; 25(3): 418-27, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16325968

RESUMO

BACKGROUND AND AIMS: Various anti-inflammatory therapies, including dietary omega-3 polyunsaturated fatty acids (PUFA) supplementation, have been investigated in cystic fibrosis (CF) patients. To further explore this nutritional approach, biological effects of an omega-3 PUFA oral liquid supplementation were measured in 17 CF patients in a double-blind, randomized, crossover without a washout period and placebo-controlled study. METHODS: CF patients (age: 18+/-9 year; weight: 43+/-13 kg) received a liquid dietary supplementation either enriched or not in omega-3 PUFA (390-1170 mg/day according to patient weight) during two 6-month periods. RESULTS: Increase in eicosapentaenoic acid was observed in neutrophil membrane following omega-3 PUFA dietary supplementation (from 0.7+/-0.6 to 1.6+/-0.6 micromol%, P<0.01). The leukotriene B(4) (LTB(4))/leukotriene B(5) (LTB(5)) ratio was decreased (from 72+/-27 to 24+/-7, P<0.001) in CF patients taking omega-3 PUFA supplements. In contrast, omega-3 PUFA supplementation affected neither internalization of IL-8 receptors following IL-8 exposure, nor IL-8-induced neutrophil chemotaxis. CONCLUSION: Our results show that omega-3 PUFA are incorporated in neutrophil membranes. The subsequent decrease in LTB(4)/LTB(5) ratio suggests that, in such conditions, neutrophils may produce less pro-inflammatory mediators from the acid arachidonic pathway. These data indicate that omega-3 PUFA intake may have anti-inflammatory effect that still need to be assessed by long-term studies following large groups of patients.


Assuntos
Fibrose Cística/terapia , Ácidos Graxos Ômega-3/administração & dosagem , Adolescente , Adulto , Membrana Celular/química , Quimiotaxia de Leucócito/efeitos dos fármacos , Criança , Estudos Cross-Over , Suplementos Nutricionais , Ácido Eicosapentaenoico/análogos & derivados , Ácido Eicosapentaenoico/sangue , Humanos , Interleucina-8/farmacologia , Leucotrieno B4/análogos & derivados , Leucotrieno B4/sangue , Neutrófilos/ultraestrutura , Placebos , Receptores de Interleucina/efeitos dos fármacos , Receptores de Interleucina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA